Brands of Cefoperazone in Kenya
Bactacef, Swiss Parenterals (Pvt.) Ltd
Cebanex, Orchid
Cefobact ,Inject Care Parenterals Pvt. Ltd
Cefocel, Zawadi Healthcare Ltd
Cesalac, Flamingo
Fytobact ,cadila Pharmaceuticals (EA) Ltd
Injlin , Inject Care Parenterals Pvt Ltd
Inno-bact , Innocia Lifesciences Pvt. Ltd.
Cefoperazone is a third-generation cephalosporin antibiotic
It is one of few cephalosporin antibiotics effective in treating Pseudomonas bacterial infections which are otherwise resistant to these antibiotics.
Cefoperazone/sulbactam is a co-formulation with sulbactam.
It was patented in 1974 and approved for medical use in 1981
Mechanism of Action
Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase-producing organisms.
Spectrum of bacterial susceptibility
Cefoperazone has a broad spectrum of activity and has been used to target bacteria responsible for causing infections of the respiratory and urinary tract, skin, and the female genital tract. The following represents MIC susceptibility data for a few medically significant microorganisms.
- Haemophilus influenzae: 0.12 – 0.25 µg/ml
- Staphylococcus aureus: 0.125 – 32 µg/ml
- Streptococcus pneumoniae: ≤0.007 – 1 µg/ml
DRUG INTERACTIONS
Alcohol:
A disulfiram-like event ,may occur when used with alcohol.,this has been attributed to the N-methylthiotetrazole (NMTT or 1-MTT) side chain . Patients should avoid alcohol during treatment
Probenecid : may decrease renal clearance of Cefoperazone
ADVERSE EFFECTS
Cefoperazone contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Cefoperazone in Kenya
Cefoperazone in Kenya
Cefoperazone in Kenya
Cefoperazone in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: Not Recommended
Routes of Administration: Im
Bioavailability: Not Available
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: Not Available
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , â„ž-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
- Cefoperazone
| CAS Number | |
|---|---|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Drug Images
References/ Citation:
- PPB Drugs Retention Register
- Xin, Xiaojuan, et al. “A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.” Annals of clinical microbiology and antimicrobials 12.1 (2013): 38.
- Gao, Chunlu, et al. “Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.” European journal of clinical pharmacology 72.7 (2016): 823-830.
- Wexler, H. M., and S. M. Finegold. “In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.” Antimicrobial agents and chemotherapy 32.3 (1988): 403-406.